The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount ...

Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE. The row over Kadcyla has lasted three years, and has been one of ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...